Search

Model Medicines, in collaboration with researchers from Icahn School of Medicine at Mount Sinai and University of California, San Diego, has developed MDL-001, a groundbreaking broad-spectrum antiviral therapy effective against various viral pathogens, including SARS-CoV-2, Influenza, Norovirus, and Hepatitis C. The preclinical studies show that MDL-001 has comparable efficacy to remdesivir and significantly reduces viral accumulation in the lung. With its oral bioavailability, favorable pharmacokinetic profile, and safety demonstrated in clinical trials, MDL-001 represents a promising advancement in antiviral therapeutics, addressing critical gaps in pandemic preparedness. [Extracted from the article]

A patent application titled "Methods For Treating Or Preventing Viral Infection" was published online by inventors from Denmark. The application focuses on using plasmacytoid dendritic cells (pDC) to treat viral infections, particularly COVID-19 caused by SARS-CoV-2. The method involves administering pDCs and potentially anti-inflammatory agents to mitigate the severity of viral infections, emphasizing the importance of understanding immune responses to develop targeted treatments. The application highlights the need for methods that promote antiviral responses without triggering excessive inflammatory reactions, offering potential avenues for future research and treatment development. [Extracted from the article]

Roche Molecular Systems Inc. has been issued a patent for detecting SARS-CoV-2, Influenza A, and Influenza B in biological samples. The patent provides methods for rapid and simultaneous detection of these viruses using real-time reverse-transcription polymerase chain reaction (RT-PCR). The need for accurate differentiation of these infections is crucial for medical decision-making and infection control efforts. The patent outlines specific primers, probes, and kits designed for this purpose. [Extracted from the article]

A patent was issued to inventor Erik Johan Niemela for a carrier designed for targeted delivery to a host, with the assignee being Finncure Oy. The carrier is intended to prevent or reduce the spread of pathogens, including coronaviruses like SARS-CoV-2, by using nano- and/or micromaterials-based carriers to deliver drugs specifically to target cells and tissues. The carrier system aims to inhibit pathogen binding and entry to host cells, potentially enhancing therapy by targeting specific cells and delivering drugs with lower impact on other cells. The patent outlines various embodiments and applications of the carrier system for personalized treatment or diagnostics related to diseases caused by pathogens. [Extracted from the article]

Respiratory Health Technologies Inc. has been issued a patent for apparatuses and methods to attenuate viruses using heat, particularly focusing on the common cold caused by rhinoviruses. The patent aims to provide a more consistent treatment for reducing viruses and includes features such as a virus attenuator with heaters, control boards, and sensors. The invention is designed to heat gas to a virus-attenuating temperature and provide this heated gas to patients through breathing devices, potentially offering a new approach to addressing respiratory illnesses like the common cold, SARS, and COVID-19. [Extracted from the article]

The patent application titled "Bioactive Peptides And Methods Of Use Thereof" discusses the treatment of cytokine release syndrome (CRS) and acute respiratory distress syndrome (ARDS) caused by infections like COVID-19. The application proposes a novel method using peptides to modulate the interaction between CD40 complex and CD154 proteins to reduce inflammation and cytokine levels. This treatment approach aims to address the severe immune response associated with CRS and ARDS, offering potential therapeutic benefits for patients with these conditions. [Extracted from the article]

Researchers have submitted a patent application for coated substrates with anti-viral properties to address concerns about airborne transmission of diseases like COVID-19. The inventors aim to improve personal protective equipment and air filters to enhance protection against viruses and infectious diseases. The coated substrates include mineral oxide and iron oxide particles, with the goal of reducing breathing resistance and increasing effectiveness in trapping viruses. [Extracted from the article]

A patent has been issued for an expandable system designed to purify and disinfect air, particularly targeting airborne viruses like SARS-CoV-2. The system aims to protect individuals and facilities from COVID-19 and other viruses by destroying or neutralizing them outside the human body. It includes features such as UV-C chambers, filters, and air disinfection units to prevent the spread of harmful pathogens in enclosed spaces. The patent, filed by Perumala Holdings LLC and inventor Madhavan Pisharodi, offers a solution to address the challenges posed by airborne viruses and microorganisms in various settings. [Extracted from the article]

A patent has been issued for compositions and methods for treating SARS-CoV-2 infections by the Morehouse School of Medicine. The patent focuses on the use of virus-inhibiting secretion modulating region (VI-SMR) peptides derived from HIV-1 Nef to treat viral infections, including SARS-CoV-2. These peptides aim to prevent viral replication and spread by modulating the secretion of extracellular vesicles that play a role in viral pathogenesis. The patent provides a potential therapeutic option for treating coronavirus infections, addressing the urgent need for effective antiviral agents against SARS-CoV-2. [Extracted from the article]

A patent application titled "Antiviral Antisense Oligonucleotide" was published online by Nippon Shinyaku Co. Ltd., targeting genomic RNA of SARS-CoV-2. The invention aims to provide a novel therapeutic agent with antiviral effects on SARS-CoV-2, SARS-CoV-1, and MERS-CoV. The application focuses on developing an antisense oligonucleotide or a pharmaceutical composition to combat viral infections, particularly related to COVID-19. [Extracted from the article]

A patent application for a "Protective Isolation Hood" has been published online by Ningbo Careful Special Cars Co. Ltd. The invention aims to provide protection during the transfer of COVID-19 patients from home to ambulance and from ambulance to hospital isolation ward. The hood creates a safe negative pressure environment, filters aerosols, and disinfects virus-containing aerosols, ensuring the safety of medical staff and patients during transportation. The invention addresses shortcomings in existing technologies and aims to improve safety and comfort during emergency medical transfers. [Extracted from the article]

The patent application by Thomas E. Wagner and Orbis Health Solutions LLC focuses on developing nucleic acid vaccines to treat or prevent infectious diseases caused by viruses, bacteria, or other microbes, with a specific emphasis on addressing the global public health threat posed by COVID-19. The vaccine platforms described in the application aim to efficiently deliver nucleic acids to antigen presenting cells, inducing a robust immune response to immunogenic peptides encoded by the nucleic acids. By utilizing yeast cell wall particles, lysosome-evading components, and nucleic acid sequences encoding immunogenic peptides, the vaccines seek to stimulate the immune system and prevent infectious diseases like COVID-19. [Extracted from the article]

A patent application titled "ELDERBERRY EXTRACT FOR USE IN A METHOD OF PREVENTING OR TREATING A SARS-CoV-2 INFECTION" was published online on January 9, 2025, by inventors from various locations. The application highlights the potential benefits of elderberry extract in preventing or treating SARS-CoV-2 infections, emphasizing the need for effective treatments and immune system boosters. The extract contains anthocyanins and polyphenols, with specific concentrations and molecular weight fractions outlined for optimal efficacy. The application also discusses methods of preparing the extract and its administration to patients at different stages of infection. [Extracted from the article]

A patent application titled "Systems And Methods For Screening Asymptomatic Virus Emitters Using Diversifiers For Noise Reduction" was published online by inventors Hopper and Palacios, assigned to Hyperspectral Corp. The system involves using light sources, sample devices, vortex masks, detectors, and processors to detect and measure wavelength intensities impacted by exhaled samples for virus screening. The method aims to address challenges in wide-scale screening for pathogens, such as COVID-19, by identifying asymptomatic carriers to reduce virus spread effectively. The patent application outlines a novel approach to screening for infectious diseases that may have significant health consequences. [Extracted from the article]

A patent was issued for a selective attachment device with multiple fluid sources for maintaining positive fluid pressure by Legacy Innovation Inc. The device aims to improve ventilation for patients with severe symptoms of COVID-19 or ARDS by providing a less invasive and infection-risk-free alternative to traditional ventilators. The device allows for the continuous flow of fluid during transfer between fluid sources, addressing the critical seconds of potential lung collapse during transport ventilation. This innovation seeks to enhance medical care in various settings, including remote locations with limited access to oxygen supplies. [Extracted from the article]

A patent application titled "Diagnostic Platform For Testing Exhaled Breath Condensate And Universal Biosensor" was published online by inventors John J. Daniels and Shekhar WADEKAR. The invention aims to detect biomarkers of various biological agents, including COVID-19, in exhaled breath samples. The application describes devices and methods for testing and monitoring physiological conditions in humans and animals using electronic biosensors and biomarker concentrators. The technology offers a less invasive and more user-friendly approach to sample collection and testing for pathogenic infections like SARS-CoV-2. [Extracted from the article]

A patent has been issued for an ultraviolet pathogen disinfection system developed by Luv Systems Inc. The system aims to eliminate pathogens, including COVID-19, from public and private spaces by emitting UV light to inactivate airborne and surface-deposited pathogens. The system includes a UV light source, a controller, and a UV sensor to monitor and adjust the dosage of UV light emitted for effective pathogen inactivation. This technology could help restore society by reducing the risk of infection in public spaces, especially during times of pandemics like COVID-19. [Extracted from the article]

A patent application has been submitted for an antimicrobial barrier device designed to prevent bacterial, fungal, and viral contamination of personal luggage items such as purses, shoulder bags, and totes. The device, known as PURSEMASK(TM), aims to address the increased awareness of pathogenic contamination and transmission risks, particularly in light of the COVID-19 pandemic. The invention provides a protective barrier envelope or sleeve made of non-porous material to prevent microbial passage and includes securing means to affix the device securely to the bottom portion of the purse or luggage item. [Extracted from the article]

A patent application has been submitted for a diagnostic platform that focuses on testing exhaled breath condensate for biomarkers related to various respiratory ailments, including COVID-19. The invention aims to provide a less invasive and more user-friendly method for detecting biomarkers indicative of pathogenic infections, such as SARS-CoV-2. By concentrating target biomarkers in exhaled breath condensate samples, the testing system could offer a simpler and more effective approach to screening for infections and monitoring physiological conditions in humans and animals. [Extracted from the article]

The patent application titled "Supramolecular Filaments Based Viral Particle Capture For Prevention And Therapy Of Viral Infection" discusses a novel approach to combat viral infections, particularly focusing on coronaviruses like SARS-CoV-2. The invention involves a supramolecular filament that includes an ACE2-binding ligand peptide amphiphile, a self-assembling filler peptide amphiphile, and a soluble ACE2 with an ACE2 inhibitor. This innovative approach aims to inhibit viral entry into host cells and treat or prevent respiratory illnesses like COVID-19 by delivering the supramolecular filament through a respirable aerosol or nasal spray. [Extracted from the article]

Nicholas E. Calio, President and CEO of Airlines for America (A4A), has announced his retirement at the end of 2025 after 14 years of leadership. During his tenure, Calio focused on shaping legislative and regulatory policies to improve air travel and cargo shipping. He played a crucial role in navigating challenges such as the 5G C-Band implementation and the COVID-19 pandemic, advocating for industry support and safety measures. Calio's successor will be chosen by A4A Board Chairman Scott Kirby and Vice Chairman Robert Isom. [Extracted from the article]

Researchers have submitted a patent application for "Multivalent Carriers And Related Vaccine Compositions" aimed at developing vaccines against viral disorders, particularly targeting coronaviruses like SARS-CoV-2. The vaccine composition includes a multivalent carrier associated with multiple coronavirus antigens, such as spike proteins and nucleocapsid proteins, displayed on the carrier's surface. The method involves immunizing mammals with this vaccine to obtain B cells producing cross-reactive antibodies, potentially offering protection against various coronaviruses. [Extracted from the article]

A patent has been issued for an RNA-based vaccine by Glaxosmithkline Biologicals SA to combat emerging SARS-CoV-2 variants. The vaccine targets specific mutations in the spike protein of the virus to enhance immune responses. This development aims to address the challenges posed by new variants of the virus and the need for ongoing vaccine adaptation. [Extracted from the article]

The article discusses the development of a universal vaccine by Dx&Vx, utilizing Ferritin-based Virus-Like Particle (VLP) technology to combat infectious diseases like COVID-19. This innovative vaccine platform aims to induce strong immune responses by mimicking the structural characteristics of target viruses and stimulating both humoral and cellular immune systems. Clinical trials have shown promising results, with the vaccine demonstrating stability at room temperature and the potential for broad mutation coverage. The Ferritin-based VLP vaccine is positioned as a technologically superior and versatile option for future pandemic responses against various lethal viruses. [Extracted from the article]

A patent application titled "Digital Vaccine System, Method And Device" was published online by inventors from various locations. The application focuses on a personal health system that uses a digital vaccine platform to determine pathogen risk and provide recommendations based on user characteristics. The system aims to reduce the risk of infectious diseases by considering various factors such as age, location, and occupation. The application highlights the importance of vaccines in combating infectious diseases and the challenges associated with achieving 100% efficacy. [Extracted from the article]

A patent application has been filed for a fusion protein that combines the SARS-CoV-2 spike protein with a hepatitis B surface antigen, aiming to develop a new vaccine against COVID-19. The fusion protein self-assembles into nanoparticles that could potentially elicit a strong and long-lasting immune response when administered to mammalian subjects. This innovative approach seeks to address the ongoing need for effective and improved COVID-19 vaccines. [Extracted from the article]

Researchers Choudhry and Henley have submitted a patent application for an "Antigen Delivery Platform And Methods Of Use" that aims to develop novel vaccine strategies that mimic and modulate physiological immune responses. The application focuses on cellular vaccines, allogeneic universal vaccine generation cells, and poly-pathogenic polyvalent universal cellular vaccines that protect against multiple viral variants, including COVID-19 and respiratory syncytial virus. The patent application outlines genetically engineered human cells designed to induce immune responses to antigens, with a focus on enhancing immune protection and addressing emerging pandemic variants. [Extracted from the article]

Researchers have submitted a patent application for a new betacoronavirus attenuated strain, aiming to develop a novel vaccine for COVID-19. The strain includes specific mutations related to temperature sensitivity and growth reduction, potentially offering improved attenuation. This invention seeks to address the limitations and side effects associated with current gene vaccines, providing a promising alternative for future immunization efforts. [Extracted from the article]

A patent application titled "Identification And Uses Of Peptide Sequences Of Sars-Cov-2 T Cell And B Cell Epitopes" was published online on January 2, 2025, by inventors from Hong Kong. The application focuses on developing new compositions and methods to elicit an immune response to SARS-CoV-2 and other coronavirus infections by identifying T-cell and B-cell epitopes. The invention aims to improve the efficacy of COVID-19 treatments and provide protection against severe disease and hospitalization, addressing the need for robust neutralizing antibody responses in combating the pandemic. [Extracted from the article]

Researchers have submitted a patent application for "Stable Coronavirus Proteins And Vaccine Compositions Thereof" to address the ongoing threat of the SARS-CoV-2 virus and future emerging coronaviruses. The application focuses on enhancing the stability of the spike protein through specific amino acid mutations to improve vaccine shelf-life. The patent application details methods for identifying mutations and aligning sequences to develop effective vaccines against coronaviruses. [Extracted from the article]

The article discusses the evolution of vaccine technologies in response to the COVID-19 pandemic, focusing on the development of a nanoparticle-based universal coronavirus vaccine by DX&VX. This novel vaccine aims to provide cross-immunity against coronavirus mutations, with the ability to be administered orally or nasally for both mucosal and systemic immunity. Unlike traditional vaccines, the nanoparticle vaccine targets multiple virus regions, offering broader protection against variants and potentially simplifying storage and distribution. Clinical trials have shown promising results, positioning this vaccine as a potential bio-defense technology for future pandemics. [Extracted from the article]

iHealth Labs, Inc. received a Silver award in the Best New Product, Healthcare and Medical category at the 14th Annual Best in Biz Awards for its 3-in-1 Flu A&B/COVID-19 antigen rapid test. This at-home test, approved by the FDA for Emergency Use Authorization, provides results in 15 minutes and helps differentiate between flu and COVID-19 symptoms for appropriate treatment. The test aims to reduce the burden on medical facilities during peak illness periods and has been recognized for its innovation and social responsibility. [Extracted from the article]

Researchers have submitted a patent application for a nucleic acid-based multiplexed lateral flow assay for disease detection, targeting respiratory diseases such as SARS-CoV-2 and Flu A/B. The application aims to address the challenge of diagnosing co-infections of SARS-CoV-2 and Flu A/B, which can lead to more severe symptoms. The proposed assay offers advantages such as user-friendliness, affordability, and portability for rapid and accurate testing to differentiate between respiratory diseases. The patent application outlines the use of antisense oligonucleotides in a lateral flow assay to provide fast and accurate results for disease detection. [Extracted from the article]

A patent was issued for an apparatus and related method for proximity awareness by Lopos BV, designed to improve proximity awareness in various environments, including hazardous and bio-chemically dangerous settings. The invention aims to ensure physical separation between individuals and objects, particularly in contexts like construction sites, hospitals, and during pandemics like COVID-19, SARS, and Ebola outbreaks. The technology utilizes Ultra-Wide Band interfaces, stimulus generation, and predetermined rules to enhance proximity awareness and minimize risks of contagion or infection spread. [Extracted from the article]

A patent application titled "Broadly Neutralizing Nanobodies For Coronavirus And Uses Thereof" was published online on January 2, 2025, by inventors SHI, Yi and XIANG, Yufei. The nanobodies described in the patent application are effective in reducing coronavirus viral load and preventing and treating coronavirus infections, particularly SARS-CoV-2. These nanobodies have potential therapeutic and diagnostic applications due to their small size, solubility, stability, and low immunogenicity. The patent application outlines various claims related to the amino acid sequences and multimeric forms of the nanobodies. [Extracted from the article]

The patent application titled "A Recombinant Construct For Screening Drugs Against Sars-Cov-2 Spike Protein" discusses the role of trypsin-like proteases in facilitating coronavirus infections and the development of an in vitro assay system for drug screening against SARS-COV-2 spike protein. The inventors have designed a substrate involving the spike protein's cleavage region, a reporter protein, and a cellulose binding domain for this purpose. The assay system is based on the principle that more efficient cleavage of the substrate by enzymes results in a higher bioluminescent signal, making it a potential target for antiviral therapeutics. [Extracted from the article]

A patent application has been filed for the use of wild boar cathelicidin peptide variants and vectors in managing coronavirus infections, specifically targeting SARS-CoV-2. The method involves administering peptides or vectors encoding peptides to treat or prevent viral infections, particularly in older individuals or those with severe acute infections. The patent application highlights the potential of antimicrobial peptides as antiviral therapies against COVID-19, emphasizing the need for improved treatments for coronavirus infections. [Extracted from the article]

A patent has been issued for the treatment of pneumonia and ARDS using inhibitors of C5a and IL-6 activity. The patent discusses the role of C5a and IL-6 in inflammation and immune response, particularly in the context of COVID-19 infections caused by SARS-CoV-2. The treatment method involves administering inhibitors of C5a and IL-6 activity, such as vilobelimab and tocilizumab, to patients in need. [Extracted from the article]

Researchers have submitted a patent application for "Disinfection Robots And Disinfection Methods" to address hygiene concerns in public transportation, particularly during the COVID-19 pandemic. The invention aims to provide robotic systems for cleaning and disinfection in public spaces, such as train and aircraft cabins, to enhance consistency, reduce risks of infection, and improve efficiency. The robots are designed to be small, light, and flexible, with atomization systems for effective disinfection, contributing to public safety and confidence in public transits. [Extracted from the article]

The United Services Automobile Association has been issued a patent for a method and system designed to accurately track and inform about health and safety in group settings, particularly in the context of contagious illnesses like COVID-19. The patent outlines various techniques for assessing and communicating group risks of developing contagious illnesses, utilizing user scores and location-based tracking for mobile devices. This innovative system aims to enhance safety measures in group settings by providing real-time information and alerts to users based on their risk levels. [Extracted from the article]